hyperCORE International Strengthens Executive Leadership Team with New Appointments

hyperCORE International, a leading collaborative network of clinical trial sites across North America, has announced updates to its executive leadership team with the appointment of Jeffrey Smyth as Vice President and Olivia McIver as Treasurer. Smyth previously served as President and Executive Director of partner site network TrueBlue Clinical Research, while McIver was Director of Clinical Operations at partner site network Applied Research Center. These strategic additions strengthen the organization's governance structure and ensure continued alignment with hyperCORE's mission of driving efficiency and excellence across its collective partner site networks.

In their new roles, Smyth and McIver bring complementary expertise to support hyperCORE's growth trajectory. They will play a key role in overseeing financial stewardship and supporting long-term sustainability initiatives for the organization. hyperCORE's partner site networks include AGA Clinical Trials; Alcanza Clinical Research; Apex Trials; Applied Research Center; Atlas Clinical Research; CaRe Clinics; Epic Medical Research; FOMAT Medical Research; TrueBlue Clinical Research; and QCR Network. Each independently operated network participates in harmonized operational frameworks that streamline study delivery at scale across the clinical research ecosystem.

Nicholas Focil, President of hyperCORE, emphasized the strategic importance of these appointments, stating that the organization's strength lies in its ability to unify best-in-class research sites through shared operational excellence. As hyperCORE continues to expand its footprint, having dedicated leadership positions for Vice President and integrated board Treasurer becomes essential to guide the leadership framework and maintain strategic mobility across the industry. The executive team expansion reflects hyperCORE's commitment to strengthening its governance structure while maintaining the operational independence of its partner networks.

Alongside these new appointments, Nicholas Focil, who also serves as CEO of FOMAT Medical Research, will continue in his role as President of hyperCORE. Mark Scullion, CEO of Atlas Clinical Research, will maintain his position as Secretary, providing trusted leadership to guide hyperCORE's next phase of growth and development. This continuity in leadership positions ensures stability while incorporating fresh perspectives from the newly appointed executives.

hyperCORE International represents a partner site network of leading clinical research site organizations, boasting over 80 active trial sites across five countries and two continents. The organization's partners have collectively completed more than 7,500 studies involving over 150,000 randomized participants. Each partner member operates independently while integrating harmonized operational frameworks designed to optimize efficiency, standardization, and excellence in clinical trial execution. The organization remains committed to advancing clinical research through safe, ethical, and timely studies, efficient enrollment processes, and superior retention rates, empowered by its members' recognition for performance, quality, and innovation in the clinical research field.